Literature DB >> 16469630

New contralateral vesicoureteral reflux following dextranomer/hyaluronic Acid implantation: incidence and identification of a high risk group.

James M Elmore1, Andrew J Kirsch, Robert H Lyles, Marcos R Perez-Brayfield, Hal C Scherz.   

Abstract

PURPOSE: To our knowledge the incidence of NCVUR following the endoscopic treatment of VUR with Dx/HA has not been reported previously. We evaluated the outcomes in a group of patients to determine the incidence, and to attempt to identify risk factors.
MATERIALS AND METHODS: A total of 126 children with primary unilateral VUR underwent unilateral Dx/HA implantation at our institutions. The incidence of NCVUR was determined by postoperative VCUG. Indications for surgery, patient age and gender, preoperative grade of VUR and volume of Dx/HA injected were assessed as possible risk factors for NCVUR.
RESULTS: Of the patients 96 (76.2%) were female, and mean age was 4.8 years. The principal indications for Dx/HA implantation were persistent reflux in 56 patients (44.4%) and primary therapy in 51 (40.5%). At followup VCUG 17 patients (13.5%) had NCVUR. No variable independently appeared to influence the incidence of NCVUR. Statistical analysis suggests that females younger than 5 years have an increased incidence of NCVUR (13 of 62, or 21% vs 4 of 64, or 6.3% of the remaining patients, p = 0.016).
CONCLUSIONS: NCVUR occurred in approximately 13% of our patients. Patients with higher preoperative VUR grade or a lower number of preoperative VCUGs and those undergoing treatment as primary therapy did not have an increased incidence. Girls younger than 5 years had the highest incidence of NCVUR, and initial bilateral injection may be a consideration for this group. Further effort directed at identifying the etiology and risk factors for NCVUR is needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16469630     DOI: 10.1016/S0022-5347(05)00405-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Dextranomer/Hyaluronic Acid implantation for vesicoureteral reflux.

Authors:  Ellen Shapiro
Journal:  Rev Urol       Date:  2007

2.  The Deflux experience in Canada generates both optimism and queries.

Authors:  Karen Psooy
Journal:  Can Urol Assoc J       Date:  2007-03       Impact factor: 1.862

3.  The treatment of vesicoureteral reflux in children by endoscopic sub-mucosal intra-ureteral injection of dextranomer/hyaluronic acid: A case-series, multi-centre study.

Authors:  Osama Bawazir
Journal:  Electron Physician       Date:  2017-04-25

4.  Endoscopic treatment of vesicoureteric reflux with Deflux: a Canadian experience.

Authors:  Luis A Guerra; Priya Khanna; Michele Levasseur; John G Pike; Michael P Leonard
Journal:  Can Urol Assoc J       Date:  2007-03       Impact factor: 1.862

5.  Endoscopic treatment of vesicoureteral reflux in pediatric patients.

Authors:  Jong Wook Kim; Mi Mi Oh
Journal:  Korean J Pediatr       Date:  2013-04-22

6.  Clinical value of persistent but downgraded vesicoureteral reflux after dextranomer/hyaluronic acid injection in children.

Authors:  Minki Baek; Min Young Kang; Hahn-Ey Lee; Kwanjin Park; Hwang Choi
Journal:  J Korean Med Sci       Date:  2013-07-03       Impact factor: 2.153

7.  Endoscopic bulking materials for the treatment of vesicoureteral reflux: a review of our 20 years of experience and review of the literature.

Authors:  Boris Chertin; Stanislav Kocherov; Leonid Chertin; Alaeddin Natsheh; Amicur Farkas; Ofer Z Shenfeld; Sarel Halachmi
Journal:  Adv Urol       Date:  2011-04-06

8.  The Value of PIC Cystography in Detecting De Novo and Residual Vesicoureteral Reflux after Dextranomer/Hyaluronic Acid Copolymer Injection.

Authors:  B W Palmer; M Hemphill; K Wettengel; B P Kropp; D Frimberger
Journal:  Int J Nephrol       Date:  2011-07-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.